These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 38612996)

  • 1. Omega-3 (
    Djuricic I; Calder PC
    Nutrients; 2024 Mar; 16(7):. PubMed ID: 38612996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
    Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
    Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.
    Kar S
    Am J Ther; 2014; 21(1):56-66. PubMed ID: 21975796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation.
    Radbakhsh S; Katsiki N; Santos RD; Mikhailidis DP; Mantzoros CS; Sahebkar A
    Metabolism; 2022 Jul; 132():155211. PubMed ID: 35533891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
    Singh S; Arora RR; Singh M; Khosla S
    Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
    Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
    Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.
    Quispe R; Alfaddagh A; Kazzi B; Zghyer F; Marvel FA; Blumenthal RS; Sharma G; Martin SS
    Curr Atheroscler Rep; 2022 Jul; 24(7):571-581. PubMed ID: 35499805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study.
    Kobayashi Y; Fujikawa T; Haruna A; Kawano R; Ozawa M; Haze T; Komiya S; Suzuki S; Ohki Y; Fujiwara A; Saka S; Hirawa N; Toya Y; Tamura K
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256336
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipid lowering therapy: implications of recent clinical trials.
    Backes JM; Hilleman DE
    Future Cardiol; 2024 Feb; 20(2):89-98. PubMed ID: 38226457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in the Clinical Effects of the Omega-3 Polyunsaturated Fatty Acids DHA and EPA in Cardiovascular Disease-Possible Causes and Future Considerations.
    Michaeloudes C; Christodoulides S; Christodoulou P; Kyriakou TC; Patrikios I; Stephanou A
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes.
    Bittner VA; Jacobson TA; Ballantyne CM; Guyton JR
    J Clin Lipidol; 2020; 14(1):4-15. PubMed ID: 32192643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
    Nakao K; Noguchi T; Asaumi Y; Morita Y; Kanaya T; Fujino M; Hosoda H; Yoneda S; Kawakami S; Nagai T; Nishihira K; Nakashima T; Kumasaka R; Arakawa T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Yamamoto H; Hamasaki T; Yasuda S
    Trials; 2018 Jan; 19(1):12. PubMed ID: 29310688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists.
    Patel D; Busch R
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):524-532. PubMed ID: 34191622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.